Many studies support the cardioprotective effects of folic acid (FA). We aimed to evaluate the utility of FA supplementation in preventing the development of atherosclerotic in low-density lipoprotein receptor-deficient (LDLRÀ/À) mice and to elucidate the molecular processes underlying this effect. LDLRÀ/À mice were randomly distributed into four groups: control group, HF group, HF + FA group and the HF + RAPA group. vascular smooth muscle cells (VSMCs) 
the synthesis of extracellular matrix proteins. 4, 5 VSMCs exhibit a contractile phenotype characterized by the expression of contractile marker such as a-SMA and synthetic phenotype characterized by the expression of synthetic marker osteopontin (OPN). 3, 6 Therefore, the regulation of the VSMC phenotype may be an alternative strategy for effective atherosclerosis prevention and treatment.
Folic acid (FA) is a water-soluble vitamin B that is essential for amino acid metabolism, also naming it vitamin B9. 7 In the past decade, epidemiological studies have shown that FA supplements can prevent neural tube defects, 8 reduce the risk of megaloblastic anaemia 9 and prevent some malignancies. 10 It has also been demonstrated that FA has anti-inflammatory, 11 anti-oxidative 12 and antiapoptotic effects. 13 FA also exhibits a cardioprotective effect, 14 and it has been reported that dietary supplementation with FA can improve endothelial function. 15 Additionally, Huo et al 16 reported
that FA supplementation significantly reduced the risk of stroke among hypertensive adults in China without a prior history of stroke or myocardial infarction.
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates various cellular processes including proliferation, growth, migration and differentiation. 17 It has been reported that the VSMC switch from a contractile phenotype to synthetic phenotype is associated with mTOR/p70S6K activation in atherosclerotic lesions. 18, 19 However, the regulation of the mTOR/ p70S6K signalling pathway is still not fully understood. Therefore, in this study we aimed to determine the ability of FA supplementation to delay the development of atherosclerosis lesions and to analyse the effects of FA on VSMC dedifferentiation through the mTOR/ p70S6K signalling pathway in low-density lipoprotein receptor-deficient (LDLRÀ/À) mice. 
| MATERIALS AND METHODS

| Materials
| Animal models
Twenty 6-week-old male homozygous LDLRÀ/À mice on C57BL6/J background were purchased from the model animal research centre of Nanjing University (Nanjing, China 
| Serum biochemical determinations
An automatic biochemistry analyser (Olympus AU2700, Japan) was used to measure serum concentrations of total cholesterol (TC), triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C).
The level of low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald formula. 
| Immunohistochemistry analysis
The aortic roots were harvested and fixed in 4% paraformaldehyde for 12 hour. The aortic roots were sliced into 5 lm thick for morphometric analyses. Histological sections from the aorta were treated with 3% hydrogen peroxide to block endogenous peroxidase activity, and immunohistochemical staining was performed with antia-SMA and anti-OPN antibodies. The positive areas were measured in five non-overlapping fields with a DP Manager/Controller and Image-Pro Plus software.
| Western blot for a-SMA, OPN, p-mTOR, mTOR, p-p70S6K and p70S6K
Aortas and VSMCs were homogenized in ice-cold cell lysis buffer plus protease inhibitor cocktail. Protein expression in the aortas and in VSMCs was detected by Western blot analysis using the primary antibodies for a-SMA, OPN, mTOR, p-mTOR, p70S6K and pp70S6K. Each sample was harvested and separated on 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis and electrotransferred onto polyvinylidene fluoride membranes. The membrane was blocked in 5% skim milk for 30 minutes, followed by incubation with the primary antibody overnight at 4°C. The samples were then further incubated with a secondary antibody for 2 hour at room temperature. The bands were detected using an enhanced chemiluminescence reagent, and protein levels were determined by normalization to GAPDH.
| Statistical analysis
At least three independent measurements were performed for all assays. All data were reported as the mean AE standard error (SE).
Parameters were evaluated by one-way ANOVA with least significant difference (LSD) post hoc multiple comparison tests. Differences were considered to be significant at P < .05.
3 | RESULTS 
| Folic acid supplementation decreased oxidative stress and inflammation
The effects of folic acid supplementation on markers of oxidative stress and inflammation were analysed. In the HF + FA and HF + RAPA groups, the levels of SOD and GSH-Px were significantly higher than those seen in the HF group ( Figure 1A , B and C). However, MDA levels, which are a marker of oxidative damage, were decreased in the HF + FA and HF + RAPA groups. Moreover, in the HF + FA and HF + RAPA groups, IL-6, IL-1b and TNF-a levels were reduced compared with the levels seen in the HF group ( Figure 1D , E and F). These results demonstrate that FA supplementation suppressed oxidative stress and inflammation in the high-fat-fed LDLRÀ/À mice.
| Folic acid supplementation suppressed atherosclerosis plaque progression
Atherosclerotic lesions were stained using oil red O stain to determine the area of atherosclerosis in each study group. As shown in Figure 2A 
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In addition, lower LDL concentrations and increased HDL levels are known to prevent the development and progression of atherosclerosis. 26 Hyperlipidaemia causes endothelial injury and inflammation and triggers atherosclerosis. 27 Therefore, lowering lipid levels could delay the development of atherosclerosis.
In addition, prior reports have shown that FA supplementation effectively prevented atherosclerosis and reduced the concentration of serum TC. 28 Our results are consistent with those of previous studies that showed that FA supplementation significantly reduced serum mTOR/p70S6K signalling has been reported to function as a critical regulator in the development of atherosclerosis, and the inhibition of mTOR has reportedly suppressed the development of atherosclerosis. Therefore, the mTOR signalling pathway has been identified as a therapeutic target. 39, 40 Rapamycin and its analogues are widely used in preventing restenosis and suppressing atherosclerosis. 41 Jahrling et al 21 showed that rapamycin-mediated mTOR attenuation decreased the atherosclerosis lesion area in high-fat-fed LDLRÀ/À mice. In the present study, we demonstrated that FA ameliorated atherosclerosis progression via suppression of the mTOR/p70S6K signalling pathway. Furthermore, studies have shown that the mTOR/p70S6K signalling pathway is involved in VSMC dedifferentiation. 42 Ding et al 43 reported that adiponectin suppressed VSMC dedifferentiation via inhibition of mTOR C1 and its effector S6 kinase 1 (S6K1). Additionally, Zhang et al 44 demonstrated that miR-99a inhibited insulin-induced VSMC dedifferentiation via the inhibition of mTOR signalling. In the present study, we demonstrated that FA could suppress the mTOR/p70S6K signal pathway and inhibit VSMC dedifferentiation in vivo, and we found that FA through inhibiting the mTOR pathway inhibits VSMC dedifferentiation, results consistent with our previous in vitro studies. 45 However, the regulation of the mTOR/p70S6K signalling pathway and its effects on the phenotypic switching of VSMCs in atherosclerosis is still not fully understood. Recent studies have demonstrated that mTOR signalling regulates many metabolic and physiological processes, including lipid metabolism, 46 oxidative stress 40 and inflammation. 
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